-
公开(公告)号：EP4232471A1
公开(公告)日：2023-08-30
申请号：EP21799220.5
申请日：2021-10-22
-
2.发明公开
公开(公告)号：EP4138874A1
公开(公告)日：2023-03-01
申请号：EP21719664.1
申请日：2021-04-22
发明人： THOMAS, Leo
IPC分类号： A61K38/00 , A61K47/54 , C07K14/605
-
公开(公告)号：EP3966239A1
公开(公告)日：2022-03-16
申请号：EP20723153.1
申请日：2020-05-08
-
公开(公告)号：EP3939577A1
公开(公告)日：2022-01-19
申请号：EP21189804.4
申请日：2008-08-15
发明人： DUGI, Klaus , MARK, Michael , THOMAS, Leo , HIMMELSBACH, Frank
IPC分类号： A61K31/00 , A61K31/70 , A61K31/7034 , A61K9/00 , A61K9/20 , A61K9/14 , A61K9/16 , A61K9/48 , A61P1/16 , A61P3/00 , A61P5/48 , A61P9/00 , A61P9/10 , A61P13/12 , A61P25/00 , A61P27/02 , A61P31/10 , A61P43/00 , A61P5/50 , A61P3/10 , A61P3/04 , A61P3/06
摘要： The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
-
5.发明公开PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE 审中-公开药剂师ZUSAMMENSETZUNG MIT EINEM GLUCOPYRANOSYL-SUBSTITUIERTEN BENZOLDERIVAT
公开(公告)号：EP3106156A1
公开(公告)日：2016-12-21
申请号：EP16172707.8
申请日：2008-08-15
发明人： DUGI, Klaus , MARK, Michael , THOMAS, Leo , HIMMELSBACH, Frank
IPC分类号： A61K31/00 , A61K31/70 , A61K31/7034 , A61K45/06 , A61K9/00 , A61K9/48 , A61K9/16 , A61K9/14 , A61K9/20 , A61P3/10 , A61P3/04 , A61P3/06
CPC分类号： A61K31/7034 , A61K9/0019 , A61K9/145 , A61K9/1623 , A61K9/2018 , A61K9/2072 , A61K9/4858 , A61K31/70 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
摘要翻译： 本发明涉及根据权利要求1的药物组合物，其包含与DPP IV抑制剂组合的吡喃葡萄糖基取代的苯衍生物，其适用于治疗或预防选自1型糖尿病，2型糖尿病的一种或多种病症 ，糖耐量异常和高血糖。 此外，本发明涉及用于预防或治疗代谢紊乱及相关病症的方法。
-
6.发明授权PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE 有权包含吡喃酰基取代的苯衍生物的药物组合物
公开(公告)号：EP2187879B1
公开(公告)日：2016-10-12
申请号：EP08787264.4
申请日：2008-08-15
发明人： DUGI, Klaus , MARK, Michael , THOMAS, Leo , HIMMELSBACH, Frank
IPC分类号： A61K31/00 , A61K31/70 , A61K31/7034 , A61P3/10 , A61P3/04 , A61P3/06 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48
CPC分类号： A61K31/7034 , A61K9/0019 , A61K9/145 , A61K9/1623 , A61K9/2018 , A61K9/2072 , A61K9/4858 , A61K31/70 , A61K2300/00
-
公开(公告)号：EP2895505A1
公开(公告)日：2015-07-22
申请号：EP13765701.1
申请日：2013-09-17
发明人： TOLBORG, Jakob Lind , FOSGERAU, Keld , NØRREGARD, Pia , JUST, Rasmus , RIBER, Ditte , HAMPRECHT, Dieter Wolfgang , AUGUSTIN, Robert , THOMAS, Leo , RIST, Wolfgang
IPC分类号： C07K14/605 , A61K38/26
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供了用于治疗肥胖和过量体重，糖尿病和其他相关代谢紊乱的材料和方法。 特别地，本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性来介导其作用。
-
8.发明授权GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE 有权吡喃葡萄糖基取代苯甲腈衍生物，这样的化合物的药物组合物，它们的使用及其制造方法
公开(公告)号：EP2024352B1
公开(公告)日：2013-04-24
申请号：EP07728702.7
申请日：2007-05-02
IPC分类号： C07D309/10 , A61K31/351
CPC分类号： C07H7/04 , A61K9/0019 , A61K9/02 , A61K9/2018 , A61K9/4866 , C07D309/10
-
9.发明授权NEUE 3-METHYL-7-BUTINYL-XANTHINE, DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL 有权NEW 3-甲基-7-丁炔基 - 黄嘌呤，它们的制备和它们作为药物
公开(公告)号：EP1797093B1
公开(公告)日：2012-05-30
申请号：EP05781895.7
申请日：2005-09-09
发明人： LANGKOPF, Elke , ECKHARDT, Matthias , HIMMELSBACH, Frank , TADAYYON, Mohammad , THOMAS, Leo , LOTZ, Ralf, R., H.
IPC分类号： C07D473/04 , A61P3/10 , A61K31/4985
CPC分类号： C07D473/00
摘要： The invention relates to novel substituted xanthines of general formula (I), wherein R1, R2, and X are defined as mentioned in the claims, the tautomers, enantiomers, diastereomers, mixtures, and salts thereof, which have valuable pharmaceutical properties, especially an inhibitive effect on the activity of the dipeptidyl peptidase-IV (DPP-IV) enzyme.
-
10.发明公开
公开(公告)号：EP2344195A2
公开(公告)日：2011-07-20
申请号：EP09782792.7
申请日：2009-09-08
发明人： MARK, Michael , EICKELMANN, Peter , LUIPPOLD, Gerd , THOMAS, Leo
CPC分类号： A61K31/522 , A61K31/506 , A61K45/06
摘要： The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
-
-
-
-
-
-
-
-
-
搜索结果
97 条记录 (耗时 0.03 秒)
